PRNewsWire
10 Jul 2026, 00:57 UTC · 17w ago
Impact · against what's priced in
Ionis Pharmaceuticals faces a severe valuation hit due to the failure of its Phase-3 CARDIO-TTRansform trial and a subsequent securities fraud investigation. AstraZeneca's valuation is also negatively impacted as the partner in the failed program.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Ionis Pharmaceuticals' Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint of reducing combined cardiovascular death and recurrent events.
So whatThe failure of a Phase-3 trial for a major program typically results in a significant loss of future revenue potential and a sharp decline in valuation.
More negative than 99% of claims this week
The law firm Levi & Korsinsky has launched an investigation into whether Ionis made materially false or misleading statements regarding the CARDIO-TTRansform program.
Continue reading
5 related stories
The failure of the Phase-3 CARDIO-TTRansform trial to meet its primary endpoint and the resulting 20% stock drop, coupled with a securities fraud investigation into CEO Brett Monia's prior statements, represent a major loss of future revenue potential.
Read from the article alone
No priced-in read yet
As the partner in the failed CARDIO-TTRansform trial, AstraZeneca loses the potential commercial upside of this specific cardiovascular treatment program.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 78% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company's Phase-3 CARDIO-TTRansform trial failed its primary endpoint, leading to a 20% stock price drop and a securities fraud investigation.
More negative than 79% of ticker scores this week
AstraZeneca was the partner in the failed Phase-3 CARDIO-TTRansform trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
8h ago
—
No price for AZN right now — the quote feed didn't answer.
AZN chart →—
No price for IONS right now — the quote feed didn't answer.
IONS chart →
